We must address the <scp>MASLD</scp> awareness gap, improve educational quality and prepare for the digitally quantified self-Reference-Cited by-同舟云学术

We must address the MASLD awareness gap, improve educational quality and prepare for the digitally quantified self

Published:2024-08-28 Issue:9 Volume:44 Page:2099-2101
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver International

Author:

Kopka Christopher J.¹^ORCID,Pugliese Nicola²³^ORCID,Brennan Paul N.⁴⁵⁶^ORCID,Lazarus Jeffrey V.¹⁶⁷⁸^ORCID

Affiliation:

1. Barcelona Institute for Global Health (ISGlobal) Hospital Clínic, University of Barcelona Barcelona Spain

2. Division of Internal Medicine and Hepatology, Department of Gastroenterology IRCCS Humanitas Research Hospital Rozzano Italy

3. Department of Biomedical Sciences Humanitas University Pieve Emanuele Italy

4. Division of Molecular and Clinical Medicine Ninewells Hospital and Medical School, University of Dundee Dundee UK

5. NHS Tayside, Ninewells Hospital and Medical School Dundee UK

6. The Global NASH Council Washington DC USA

7. City University of New York Graduate School of Public Health and Health Policy (CUNY SPH) New York New York USA

8. Faculty of Medicine and Health Sciences University of Barcelona Barcelona Spain

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15951

Reference20 articles.

1. Health information in short videos about metabolic dysfunction‐associated steatotic liver disease: Analysing quality and reliability

2. World Health Organization.Infodemic.2024. Accessed March 27 2024.https://www.who.int/health‐topics/infodemic#tab=tab_1

3. A global action agenda for turning the tide on fatty liver disease

4. Revolutionizing healthcare platforms: the impact of AI on patient engagement and treatment efficacy;Batra P;Int J Sci Res,2024

5. United States Food and Drug Administration.FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease.2024. Accessed March 27 2024.https://www.fda.gov/news‐events/press‐announcements/fda‐approves‐first‐treatment‐patients‐liver‐scarring‐due‐fatty‐liver‐disease